AUG 18, 2020 2:27 PM PDT

Psychedelic Medicine Reduces Inflammation from Asthma

WRITTEN BY: Annie Lennon

Aside from mental health applications, psychedelics are also known for their antiinflammatory effects. And now, a company called Eleusis has received data from a preclinical study that may pave the way for psychedelic medicines to treat antiinflammatory conditions. 

The company's researchers investigated 21 psychedelic compounds known to target the serotonin receptor 5-HT2A. Previous research conducted on mice showed that activation of this receptor has an antiinflammatory effect on tissues of the blood vessels and gut. In particular, it was shown to reduce inflammation in asthma patients. 

Aware of their antiinflammatory potential, the researchers wanted to find a psychedelic that would not have the behavioral effects of most psychedelics. As such, they looked at how each of the drugs behaved in rats with allergic asthma. Although all drugs activated the 5-HT2A receptor, they differed in the ability to prevent airway constriction. Surprisingly, the researchers noted that LSD was ineffective. 

They did, however, find that one class of psychedelics called 2,5-dimethoxyphenethylamine (2C-H) was able to reduce inflammation without the behavioral effects of LSD or other psychedelics, despite its close relationship to mescaline and amphetamines.

"One main takeaway was that the potency of a given psychedelic wasn't predicted by its psychoactive properties," says Nichols said. "LSD, which is a super-potent psychedelic that produces behavioral effects at very low doses, is a relatively weak antiinflammatory. So the cellular effects that mediate antiinflammatory responses are very different from those that are underlying the behavioral effects."

The researchers will use their new insights to develop antiinflammatory drugs that can be delivered via the eye- a delivery method that further minimizes the risk of mental side effects. They say that their results will also inform the development of new chemical entities capable of treating other diseases, including rheumatoid arthritis. 

 

Sources: Fierce BiotechScience Direct

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
SEP 10, 2020
Drug Discovery & Development
Common Painkiller Increases Risk-Taking Behavior
SEP 10, 2020
Common Painkiller Increases Risk-Taking Behavior
Researchers from Ohio State University have found that the common painkiller, paracetamol ( also known as Tylenol and Pa ...
SEP 07, 2020
Drug Discovery & Development
Improving Antirejection Medications in Heart Transplant
SEP 07, 2020
Improving Antirejection Medications in Heart Transplant
Placing patients on anti-rejection drugs is reality for all heart transplant patients. As such, recent research at Johns ...
SEP 11, 2020
Drug Discovery & Development
Novel Therapeutic for ALS
SEP 11, 2020
Novel Therapeutic for ALS
The TDP-43 protein is a well-known hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). A ...
OCT 06, 2020
Drug Discovery & Development
New Immunotherapy Drug Effective Against Lung Cancer
OCT 06, 2020
New Immunotherapy Drug Effective Against Lung Cancer
A new study has confirmed that Tecentriq, an immunotherapy drug, improves survival rates among those with newly diagnose ...
OCT 06, 2020
Cannabis Sciences
Cannabis Use May Reduce Cancer Risk by 10%
OCT 06, 2020
Cannabis Use May Reduce Cancer Risk by 10%
A recent meta-analysis of 34 studies found that cannabis use may decrease one’s risk of developing certain kinds o ...
OCT 20, 2020
Drug Discovery & Development
The Power of Extracellular Vesicles
OCT 20, 2020
The Power of Extracellular Vesicles
What are extracellular vesicles (EVs)? They are tiny nanometer sized messengers that transport themselves between cells ...
Loading Comments...